<DOC>
	<DOCNO>NCT02029586</DOCNO>
	<brief_summary>This control study determine effectiveness safety MB12066 treatment adult patient Nonalcoholic Fatty Liver Disease ( NAFLD ) except cirrhosis .</brief_summary>
	<brief_title>Therapeutic Exploratory Phase 2 Study Evaluate Safety Efficacy MB12066 Patients With Nonalcoholic Fatty Liver Disease ( NAFLD ) Except Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>NAFLD Activity Score ( NAS ) ≥ 3 ( Biopsyproven ) Alcohol consumption &gt; 20g/day Type 1 diabetes poorly control diabetes mellitus ( HbA1c ≥ 9 % ) Evidence chronic liver disease ( e.g . HBsAg positive , antiHCV positive , autoimmune hepatitis , Wilson 's disease , alpha1 antitrypsin deficiency etc . ) ALT , AST &gt; 5X upper limit normal Serum creatinine ≥ 2mg/dl Fibrosis score ≥ 3 accord NASH CRN fibrosis stag system NQO1 T/T type Weight loss 5kg within 6 month Bariatric surgery within 6 month Known alcohol drug abuse last five year Insulin sensitizer , hepatoprotective agent , antioxidant , lipidlowering agent , drug induce fatty liver within 1 month</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>